Chronic anticoagulation in end-stage renal disease patients: pharmacocinetics and pharmacodynamic of a reduced dose regimen of rivaroxaban (CARD-AXA)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-505733-28-00

Enrollment

Registered

2024-04-19

Start date

2025-01-08

Completion date

Unknown

Last updated

2025-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hemodialysis

Brief summary

Area under the AUC curve (drug dosage and anti-Xa activity) for each of the 3 doses of rivaroxaban (5, 10 and 15 mg/d)

Detailed description

Occurrence of bleeding events graded according to the BARC classification during the study period

Interventions

DRUGXarelto 2.5 mg film-coated tablets

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Area under the AUC curve (drug dosage and anti-Xa activity) for each of the 3 doses of rivaroxaban (5, 10 and 15 mg/d)	—

Secondary

Measure	Time frame
Occurrence of bleeding events graded according to the BARC classification during the study period	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026